The convergence of US tariffs and the ongoing conflict in West Asia poses significant risks to Indian equity markets, particularly in the metals and pharmaceutical sectors. Sudip Bandyopadhyay highlights that Vedanta and NALCO are insulated from these challenges, benefiting from a 10% reduction in global aluminium production due to the conflict, which is likely to keep prices elevated. In contrast, Hindalco faces unique risks stemming from operational setbacks at its US subsidiary, Novelis. In the steel sector, while most Indian producers are insulated from direct tariff impacts, Tata Steel could be affected due to its European operations. In pharmaceuticals, India's strength in generics provides a buffer against proposed US tariffs on branded drugs. However, companies like Sun Pharma, which relies heavily on US branded sales, and Glenmark, which plans to launch branded products in the US, face significant risks. Overall, while the metals and generic pharma sectors exhibit structural protection, specific companies require closer scrutiny.